BioSpace News Archive

LumiThera Inc., a commercial stage medical device company delivering photobiomodulation (PBM) treatment for ocular disorders and diseases, today announced it has initiated further studies with the University of Wisconsin-Milwaukee to establish the use of their Photobiomodulation platform in Diabetic Retinopathy (DR).

Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), today announced the appointment of Nina Ohara, PharmD, M.B.A., as Director, Marketing, reporting to Deanne Melloy, Aerie’s Vice President of Marketing.

Magellan Health, Inc. (NASDAQ: MGLN) today announced that it will report its earnings for the fourth quarter and full year ended on December 31, 2019 at approximately 6:30 a.m. Eastern on Friday, February 28, 2020. At 8:30 a.m.

Medtronic plc announced financial results for its third quarter of fiscal year 2020, which ended January 24, 2020.

Epizyme, Inc. (Nasdaq: EPZM), a biopharmaceutical company developing novel epigenetic therapies, today announced that management will host a conference call and webcast to discuss its fourth quarter and full year 2019 financial results and present at upcoming investor conferences

EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Vision Center Network of America, LLC (“VCNA”), a Clinically Integrated Network (“CIN”) with the aim of significantly improving the healthcare delivery system in the specialty area of ophthalmic surgery, today announced that they have entered into an purchase agreement for DEXYCU

BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) announced that the U.S. Food and Drug Administration (FDA) has accepted and filed its new drug application (NDA) for the approval of oral, once daily berotralstat (BCX7353) for the prevention of hereditary angioedema (HAE) attacks.